192 related articles for article (PubMed ID: 8485565)
21. Antimalarial therapy in SLE.
Lanham JG; Hughes GR
Clin Rheum Dis; 1982 Apr; 8(1):279-98. PubMed ID: 6749400
[No Abstract] [Full Text] [Related]
22. Hydroxychloroquine: the cornerstone of lupus therapy.
Ruiz-Irastorza G; Khamashta MA
Lupus; 2008 Apr; 17(4):271-3. PubMed ID: 18413405
[No Abstract] [Full Text] [Related]
23. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus.
Hodis HN; Quismorio FP; Wickham E; Blankenhorn DH
J Rheumatol; 1993 Apr; 20(4):661-5. PubMed ID: 8496861
[TBL] [Abstract][Full Text] [Related]
24. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus.
Wozniacka A; Lesiak A; Boncela J; Smolarczyk K; McCauliffe DP; Sysa-Jedrzejowska A
Br J Dermatol; 2008 Nov; 159(5):1124-30. PubMed ID: 18764842
[TBL] [Abstract][Full Text] [Related]
25. Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al.
Wallace DJ
Arthritis Rheum; 2010 Sep; 62(9):2824; author reply 2824-5. PubMed ID: 20872599
[No Abstract] [Full Text] [Related]
26. [Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome].
Sarzi-Puttini P; Atzeni F; Carrabba M
Minerva Med; 2003 Apr; 94(2):63-70. PubMed ID: 12858154
[TBL] [Abstract][Full Text] [Related]
27. [Effect of corticosteroids on the balance of Th cytokines in patients with systemic lupus erythematosus].
Xie HF; Li J; Shi W
Hunan Yi Ke Da Xue Xue Bao; 2002 Dec; 27(6):533-5. PubMed ID: 12658932
[TBL] [Abstract][Full Text] [Related]
28. Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide.
Hrycek A; Pochopień-Kenig G; Scieszka J
Autoimmunity; 2007 May; 40(3):217-22. PubMed ID: 17453721
[TBL] [Abstract][Full Text] [Related]
29. Quantitative and qualitative analysis of the balance between type 1 and type 2 cytokine-producing CD8(-) and CD8(+) T cells in systemic lupus erythematosus.
Amel-Kashipaz MR; Huggins ML; Lanyon P; Robins A; Todd I; Powell RJ
J Autoimmun; 2001 Sep; 17(2):155-63. PubMed ID: 11591124
[TBL] [Abstract][Full Text] [Related]
30. Antimalarials and cholesterol profile of patients with systemic lupus erythematosus.
Rossoni C; Bisi MC; Keiserman MW; Staub HL
Rev Bras Reumatol; 2011; 51(4):383-4, 386-7. PubMed ID: 21779713
[TBL] [Abstract][Full Text] [Related]
31. Antimalarial drugs in pregnancy--the North American experience.
Parke AL; Rothfield NF
Lupus; 1996 Jun; 5 Suppl 1():S67-9. PubMed ID: 8803915
[TBL] [Abstract][Full Text] [Related]
32. [The importance of determination of interleukin-10 in the blood of patients with systemic lupus erythematosus].
Scudla V; Horák P; Faltýnek L; Pospísil Z; Budíková M; Hermanová Z
Cas Lek Cesk; 1998 Jan; 137(2):44-7. PubMed ID: 9511265
[TBL] [Abstract][Full Text] [Related]
33. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus.
Ardoin SP; Sandborg C; Schanberg LE
Lupus; 2007; 16(8):618-26. PubMed ID: 17711898
[TBL] [Abstract][Full Text] [Related]
34. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor.
Zietz B; Reber T; Oertel M; Glück T; Schölmerich J; Straub RH
J Rheumatol; 2000 Apr; 27(4):911-8. PubMed ID: 10782815
[TBL] [Abstract][Full Text] [Related]
35. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E
Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488
[No Abstract] [Full Text] [Related]
36. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.
Petri M
Lupus; 1996 Jun; 5 Suppl 1():S16-22. PubMed ID: 8803905
[TBL] [Abstract][Full Text] [Related]
37. Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.
Li XB; Cao NW; Chu XJ; Zhou HY; Wang H; Yu SJ; Ye DQ; Li BZ
Ann Med; 2021 Dec; 53(1):1687-1695. PubMed ID: 34553648
[TBL] [Abstract][Full Text] [Related]
38. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
Ezra N; Jorizzo J
Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
[TBL] [Abstract][Full Text] [Related]
39. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
[TBL] [Abstract][Full Text] [Related]
40. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
